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Aim: To perform review of literature and present the long-term observation results on clinical cases with IIH. 
Material and methods: The literature review is based on PubMed search of 4057 publications, among which 
206 full text articles from the last 5 years. We present and discuss our observations on 6 clinical cases with 
different clinical characteristics and response to treatment in the long-term follow-up course. 
Results: The diagnosis was based on the clinical picture, presence of papilledema, and exclusion of other 
diseases that can cause intracranial hypertension (check-up of cerebrospinal  uid, cranial CTscan and MRI, 
exclusion of thrombosis of the cerebral venous sinuses – MRI venography). The  rst two presented patients 
underwent neurosurgical treatment (ventriculo-peritoneal shunting), because of the severe course of the disease. 
The long-term result was unfavorable. The rest 4 patients, due to the moderate severity of the disease, were 
treated conservatively with high dose Acetazolamide and titration of the dose for a minimum of 9-12 months. In 
all 4 patients there was successful recovery of visual function, absorbtion of the papilledema and retention of the 
result for a period of 2 to 4 years. 
Conclusion: The correct timely diagnosis and treatment, along with good interdisciplinary collaboration, are the 
main prerequisite factors that can prevent severe bilateral irreversible loss of visual function in patients with IIH.  
Key words: idiopathic intracranial hypertension, pseudotumor cerebry, acetazolamide, cerebrospinal  uid shunts 
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